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REFRACTORY CRANIOFACIAL PAIN
Is there a role of periodontal disease as a comorbidity?
Gisele Maria Campos Fabri1, Silvia R.D.T. Siqueira2, Caio Simione3, Cibele Nasri4,  
Manoel JacobsenTeixeira5, José Tadeu Tesseroli Siqueira6
Abstract – Objetive: To evaluate the influence of the periodontal disease (PD), a chronic infection, in patients 
with chronic craniofacial pain complaints.  Method: Twenty patients with chronic craniofacial pain and 
PD (CFP group) and 20 patients with PD (PD group) were assessed before and after periodontal treatment 
(baseline, 30 and 180 days after treatment). The paramenters evaluated were: plaque index, bleeding index, 
clinical probe insertion, Visual Analogic Scale (VAS) for pain intensity and Numerical Rating Scale (NRS) and 
Verbal Rating Scale (VRS) for the “chief complaint”.  Results: After 180 days PD was controlled in both groups 
(p<0.001); the VAS decreased in CFP group (p<0.001); “chief complaint” improved (p=0.005 and p=0.027, 
respectively in CFP and PD group). VRS showed improvement between the groups in 30 (p=0.004) and 180 
days (p=0.001).  Conclusion: These results suggest a possible influence of periodontal disease, as a comorbidity, 
in refractory craniofacial pain patients and in their pain levels.
Key woRDS: periodontal disease, orofacial pain, chronic headache, atypical facial pain.
Dor refratária crânio-facial: há algum papel para a doença periodontal como morbidade associada?
Resumo – Objetivo: Avaliar a influência da doença periodontal (DP) em pacientes com queixas de dores crônicas 
crânio-faciais. Método: Vinte pacientes com dor crônica crânio-facial e DP (CFP group) e 20 pacientes com DP 
(PD group) foram avaliados antes e depois do tratamento periodontal (baseline, 30 e 180 dias). Avaliações: 
índice de placa, índice de sangramento gingival, inserção clínica de bolsa, escala Visual Analógica (VAS) para 
a dor, escalas Numérica (NRS) e Verbal (VRS) para as “queixas principais”.  Resultados: Após 180 dias a DP 
foi controlada em ambos os grupos (p<0,001); a VAS reduziu no CFP group (p<0,001); a “queixa principal” 
melhorou (p=0,005 e p=0,027, respectivamente nos grupos CFP e PD). A VRS mostrou diferença entre os grupos 
em 30 (p=0,004) e 180 dias (p=0,001).  Conclusões: estes resultados sugerem a provável influência da doença 
periodontal, como morbidade associada, nos níveis de dor de pacientes com dores crônicas crânio-faciais.
PAlAVRAS-chAVe: doença periodontal, dor orofacial, cefaléia crônica, dor facial atípica.
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chronic craniofacial pain, like headache or facial pain, 
is a common complaint in the general population1,2 , with 
several etiologies. The treatment depends on precise 
diagnosis3,4. however, even with the correct diagnostic 
and appropriate treatment some patients are refracto-
ry and do not present the expected improvement due to 
several reasons including the presence of an undiagnosed 
associated disease3,4. 
Periodontal disease (PD) is a common chronic inflam-
matory condition at the adult population5,6. It is charac-
terized by gingival and/or alveolar bone infection7, and 
it has different levels of severity8,9. It is chronic and usu-
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ally painless, except in some cases when provoked by a 
mechanical stimuli (chewing or teeth brushing) or during 
an acute episode10. The role of the periodontal disease in 
some systemic conditions has been demonstrated. Recent 
studies have shown that it plays an important role in car-
diovascular, metabolic and neurovascular conditions11-14. 
It is characterized by a chronic inflammation and mediates 
the interaction between the immune system and pain15 
also in the trigeminal nuclei16.
In the current literature there is a lack of papers about 
the role of untreated chronic periodontal disease in pa-
tients complaining of chronic craniofacial pain, particular-
ly when the pain is refractory to the conventional treat-
ments10. To the best of our knowledge to update, there are 
no studies about the role of chronic periodontal disease, 
as a comorbidity, in patients with refractory craniofacial 
pain. Thus, the aim of this study was to evaluate the role 
of chronic periodontal disease in patients with refracto-
ry craniofacial pain. 
METHOD
In this study, 20 patients were included, who presented re-
fractory craniofacial pain and concomitant severe periodontal 
disease (CFP group). The patients included underwent to clinical 
treatment (antidepressants, NSAIDs, beta-blockers or anticon-
vulsants) for minimum 3 months. other conditions of pain, like 
TMJ, cervicogenic headache and myofascial pain were investi-
gated and the patients did not have any kind of implant tools. 
These patients were referred to the Dentistry Division of the 
hospital from the Neurology Department of the same hospital, 
where the diagnosis of their pain was made. were also includ-
ed 20 patients presenting only severe PD as controls (PD group). 
The objective of this control group was to compare the severi-
ty and improvement of the PD between the groups, before and 
after periodontal treatment.
The pain diagnosis of the CFP group was performed by two 
investigators (a neurologist and an orofacial pain dentist), ac-
cording to the International headache Society criteria (2004)3. 
Periodontal diagnosis was made by one calibrated periodon-
tist according to the criteria of the American Academy of 
Periodontology8,9. During the time of this study there were no 
changes in medication or medical treatment prescribed previ-
ously to CFP group of patients. 
were excluded patients with dental decays, dental pain with 
pulpar origin, chronic systemic diseases, psychiatric conditions 
with cognitive deficit and pregnant women.
All the patients gave informed consent to procedures ap-
proved by the ethics committee of the Medical School.
Evaluation of the “chief complaint” 
The chief complaints of both groups were evaluated accord-
ing to the following question: “What is your chief complaint or 
your main problem to look for health assistance?” The improve-
ment of their “chief complaints” was evaluated according to the 
following question: “Did you have any improvement of your chief 
complaint or main problem after the periodontal treatment?” 
And the evaluation of the improvement of their “chief com-
plaint” was made according to the following scales:
1. Numeric rating scale (NRS) ranging from 0 to 100% (0 was 
no improvement and 100 was complete improvement).
2. Verbal rating scale (VRS): NI – No improvement; lI – lit-
tle improvement (less than 25%); S – satisfactory (25 to 50% of 
improvement); G – Good (more than 75% of improvement); NP 
– No pain.
Evaluation of pain intensity of CFP group
was performed according to the visual analogical scale (VAS).
Periodontal evaluation was performed according to:
1. clinical periodontal assessment by bleeding on probing 
(BoP) and the o’leary dental plaque index (PI), as well as the 
clinical probing depths (cPD) measurements8,9.
2. Panoramic radiography of the jaw and periapical radiog-
raphy of the teeth.
Periodontal treatment
The periodontal treatment were performed by one cali-
brated periodontist according the following order: (1) detailed 
oral hygiene instructions; (2) periodontal scaling and root plan-
ning carried out in a minimum of 2 sessions and a maximum of 
four; (3) periodontal surgery by widman modified procedure; (4) 
post-operatory treatment with local care (mouthwashes with 
0.19% chlorexidine) and analgesic nonsteroidal anti-inflamma-
tory drugs (etoricoxib 90) for 72 hours. Sutures were removed 7 
days after the surgery. Antibiotic prophylaxis was prescribed ac-
cording to the American heart Association17 guidelines.
Periods of evaluation:
1. Baseline, before periodontal treatment (up to 15 days);
2. 30 days after periodontal treatment;
3. 180 days after periodontal treatment.
Pain levels and improvement of chief complaints were as-
sessed by an independent researcher.
Statistical analysis 
Data were analyzed by parametric and non-parametric tests. 
After descriptive analysis, Fisher and chi-squared tests were per-
formed to compare nominal data (e.g. gender, race, body pain). 
For numerical and ordinal data t-test (weight, height, Body Mass 
Index); Mann-whitney (chief complaint, pain intensity, chief 
complaint improvement); wilcoxon (chief complaint improve-
ment), and Friedman (pain intensity) were performed. Variance 
for repetaed measures was used for periodontal parameters18,19. 
level of significance was 5%.
RESULTS
Two patients of the PD group could not complete the 
evaluations, remaining 38 patients in the study. In the CFP 
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group, the mean age was 48.95±13.03 years old (range: 28–
73 years old) and 16 were women (80%); in the PD group, 
the mean age was 42.38±9.51 years old (range: 29–62 years 
old) and 14 were women (77.8%). Both groups were pared 
(p=1.00 for gender, p=0.207 for race, p=0.087 for mean 
age, p=0.34 for weight and p=0.80 for height).
Periodontal evaluation: from baseline to 180 days
The baseline evaluation showed that severity of the 
periodontal disease was similar in both groups and there 
were no differences between them in PI (p=0.0934), BI 
(p=0.8657) and cPD (0.1728) (Table and Fig 1).
After 30 and 180 days of the periodontal treatment, 
both groups had significant improvement in every peri-
odontal parameters when compared to the baseline eval-
uation. Improvement was similar between the groups for 
PI (p=0.5202), BI (p=0.5696) and cPD (p= 0.6068).
The “chief complaint”: from baseline to 180 days
At the baseline, chief complaint of the CFP group was 
persistent pain in the head and or face. The pain charac-
teristics of this group are described in the next item. In 
the PD group, the chief complaint was gingival bleeding, 
gingival or dental discomfort during chewing and halitosis.
The NRS showed improvement of chief complaint 
of the CFP group, 30 and 180 days after the periodontal 
treatment, comparing with the baseline period (p=0.005). 
however, the groups had different means of NRS at 30 
days with significant difference between them (p<0.001), 
which also was observed at 180 days (p<0.001). 
The VRS also showed improvement of the chief com-
plaint in both groups (Fig 2), comparing to baseline (Fisch-
er’s exact test). however, the groups had different means 
of VRS at 30 days with significant difference between them 
(p=0.004), which also was observed at 180 days (p=0.001).
Pain characteristics of the CFP group 
The craniofacial pain diagnosis was distributed along 
to the patients as follows: migraine in 9; tension-type 
headache in 6 and atypical facial pain in 5. 
At baseline, the mean duration of pain was 50.9 
months (ranging from 8 to 300 months). The location of 
pain was bilateral in 15 (75%), on the left side in 4 (20%) 
and on the right side in 1 (5%) patient; The pain complaints 
were located at (according to the patients report): face in 
7 (35%); face and teeth in 3 (15%); fronto-temporal area in 
7 (35%); and fronto-temporal area and teeth in 2 (10%) and 
face and ear in 1 (5%) . 
The mean pain intensity (VAS) of the CFP group at 
baseline was 7.11±2.08 (range from 3 to 10). Thirty (30) and 
180 days after the periodontal treatment, the VAS of CFP 
group decreased in comparison to baseline. The results of 
pain intensity are outlined in Table 1.
Presence of widespread body pain in both groups
At baseline, 75% of the patients of the CFP group re-
ported pain in other parts of the body and 39% of the 
patients of the PD group reported the same complaint 
(p=0.024). The distribution of the overall body pain was 
reported as follow: (A) CFP group: back 4 (20%), cervical 4 
(20%), several joints 4 (20%), and widespread body pain 3 
(15%). (B) PD group: inferior limbs, 5 (28%) and joints at the 
inferior limbs, 2 (11%). Pain was more diffuse and spread in 
the CFP group (p=0.001).
DISCUSSION
our data showed that the characteristics of periodon-
tal disease were similar in severity in both groups at the 
baseline, and all the patients were under control of peri-
odontal disease (Table 1), which could be observed by the 
decrease of gingival bleeding which was achieved 30 days 
after the periodontal treatment (p<0.001 in both groups, 
in comparison with baseline) and maintained for 180 days 
after (p<0.001 in both groups, in comparison with base-
line). Another expected finding of this data was the sig-
nificant differences between the groups on the pres-
ence of widespread body pain (p=0.024) and its distri-
bution (p=0.001), and the literature reports that patients 
with chronic pain have more complaints of overall body 
pain and more physical and psychiatric comorbidities 
as well18,19. The CFP group had typical characteristics of 
chronic pain patients with more complaints of pain in 
other regions of their body. 
however, the relevant finding of our data and never 
published before, was the significant reduction in the pain 
intensity (VAS) of the refractory craniofacial pain group 
(p<0.001), 30 and 180 days after the periodontal treat-
ment, in comparison with baseline. This reduction of their 
Table 1. Evaluation of pain intensity by Visual Analogue Scale (VAS) in patients with periodontal 
disease and concomitant chronic craniofacial pain (CFP Group).
Group Baseline 30 days 180 days p
cFP 
(n=20)
7.11±2.08
(3–10)
4.51±3.231
(0–10)
3.67±3.272,3
(0–10)
<0.001*
*Friedman’s test comparative periods in each group; 1,2p<0.05 comparatively with baseline; 3p>0.05 comparatively 
with 30 days.
Arq Neuropsiquiatr 2009;67(2-B)
 477
Refractory craniofacial pain
Fabri et al.
Fig 1. Evaluation of periodontal disease parameters in patients without chronic craniofacial pain (PD Group) and with chron-
ic craniofacial pain (CFP Group). There is no difference between the groups. Variance analyze (each group): *p<0.001, compar-
ative to baseline.
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pain levels reflected also in a statistically significant im-
provement of their chief complaints (p=0.005). Although 
the literature refers that the periodontal disease is pain-
less and despite these patients had no changes in their 
pain medication, 65% of the patients had improvement 
after 30 days, which increased to 80% after 180 days. Tak-
en together, these findings strongly suggest the influence 
of the periodontal disease as comorbidity in refractory 
craniofacial pain. 
we need to remember that chronic pain is a complex 
phenomenon20,21 and periodontal disease could have a 
modulating or contributing role in the refractory pain al-
though the mechanisms underlying are still not clear. In-
deed, there are also interacting factors, like emotional 
stress and pain remission periods that need to be taken ac-
count. It is important to highlight that the periodontal dis-
ease is an infectious disease and recent studies have shown 
the interaction between pain and the immune system15. 
Periodontal disease expresses neurotransmitters related to 
neurogenic inflammation7,22,23 that underline central sensiti-
zation, which allows neuroplastic changes that are present 
in chronic pain patients.20,21 Thus, it is expected that the 
CFP group could be under the influence of peripheral stim-
uli, as observed in experimental orofacial pain models15. 
Pain is a subjective and individual experience and its 
evaluation must consider the patient’s opinion about his/
her improvement28. The evaluation by an independent re-
searcher also gives more trustiness to the results,24-27.
 It is important to note that in this study although all 
the CFP group presented severe periodontal disease most 
of them did not complain about it, with the exception of 
three patients who complained about generalized dental 
pain (not from pulp origin, which was an exclusionary cri-
teria of this study). As the periodontal disease has rele-
vant prevalence at the adult population and is a common 
chronic infectious disease, that could have systemic impli-
cations if it is not treated11,12, we should consider a routine-
ly evaluation also in refractory chronic pain patients of 
the periodontal tissues. Moreover, the literature has dem-
onstrated that pain with dental origin frequently co-ex-
ists with several types of craniofacial pains (eg. headache, 
atypical facial pain, and neuropathic pain)19,26,30. hence it 
is important to consider the overlap of these conditions. 
In conclusion, our data showed that severe periodon-
tal disease can be related to refractory craniofacial pain. 
Further research is necessary to clarify the reasons under-
lying this finding. These data indicate that periodontal as-
sessment must be included as a routine in patients with 
Fig 2. Evaluation of the chief complaint, by the 
Verbal Rating Scale (VRS), 30 and 180 days af-
ter the periodontal treatment in comparison 
with baseline period. There was improvement 
in both groups but with difference between 
them. In CFP group, 65% of the patients report-
ed improvement of their pain at 30 days and 
60% at 180 days. Fischer’s exact test, compar-
ative between group: p=0.004 at 30 days and 
p=0.001 at 180days. Descriptors of VRS: NI (No 
improvement ), LI (Little improvement), S (Sat-
isfactory), G (Good), NP (No pain). 
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chronic craniofacial pain, particularly when the pain per-
sists after medical approach.
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